Stereotaxis’ Second Act

article image
ARTICLE SUMMARY:

A pioneer in endovascular robotics, Stereotaxis hit a wall just over a decade ago and was near extinction soon after. Now, with a new CEO in place, is the company finally poised to realize the potential of its technology?

St. Louis-based Stereotaxis Inc. was founded more than three decades ago, the brainchild of Matthew Hobbs, MD, a neurosurgeon who was, at the time, a graduate student working on a project to develop a magnetic guidance system for neurosurgery. After several years as a research project, the company was launched with an initial investment from venture capital firm Sanderling Ventures and in 1996, the company recruited Bevil Hogg, a former executive at DME/wheelchair company Eversty & Jennings who had prior to Stereotaxis also launched a bicycle company, Trek Bicycles, to be CEO.

Through its first couple of decades or so, Stereotaxis struggled to gain its footing. By the mid-2010s, while Intuitive Surgical Inc. was building a powerful position in robotically-assisted surgery, with a stock price appreciation that rivaled the big tech companies, Stereotaxis was going nowhere and headed for extinction.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?


Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.

All-Access

Questions?

We're here to help! Please contact us at: